Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Bone-Protecting drugs shield knee cartilage from Walk-Induced breakdown?

NCT ID NCT07881861

Knowledge-focused Sponsor: Sisli Hamidiye Etfal Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 20, 2026 · Last updated Oct 21, 2026 · Updated 1 time

Summary

Researchers are studying how a short walk affects markers of cartilage breakdown in postmenopausal women with mild-to-moderate knee osteoarthritis. Participants are grouped by whether they already take denosumab, take a bisphosphonate, or take neither. Everyone walks on a treadmill for 30 minutes at a comfortable pace, and blood samples taken just before and right after the walk measure changes in two cartilage-related proteins, COMP and MMP-3. The study asks whether the size of these changes differs depending on which bone drug a woman takes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
antiresorptive drugs (denosumab or bisphosphonates) already taken by participants
What this could lead to
If the biomarker response differs by treatment, doctors may learn whether bone drugs affect cartilage breakdown during everyday activity, which could inform future osteoarthritis research.
What could go wrong
This is a small observational comparison, not a treatment trial. Biomarker changes right after a walk may not reflect long-term cartilage health or predict symptoms, and the findings may not apply to other patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 105 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Postmenopausal women aged 60-80 years with clinically and radiographically confirmed knee osteoarthritis who meet the protocol-defined eligibility criteria. Participants are categorized according to their existing antiresorptive treatment status into denosumab, bisphosphonate, and control groups.

Ages

60 to 80 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Postmenopausal women aged 60-80 years. * DEXA-confirmed diagnosis of osteoporosis or osteopenia. * Clinically and radiographically confirmed knee osteoarthritis, with Kellgren-Lawrence grade 2 or 3 in at least one knee. * Knee MRI performed within the previous 3 months. * Bilateral hand radiographs performed within the previous 6 months. * Pain intensity of at least 20 mm on the Visual Analog Scale (VAS) during activity. * Ability to tolerate the standardized acute mechanical loading protocol consisting of 30 minutes of treadmill walking. * Non-sarcopenic status according to the STAR protocol. * Ability to provide written informed consent. Exclusion Criteria: * Inflammatory arthritis, including rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. * Active gout or calcium pyrophosphate deposition (CPPD) attack. * History of total knee arthroplasty or major knee surgery. * Intra-articular knee injection within the previous 12 months. * Change in antiresorptive therapy within the previous 6 months. * Previous osteoanabolic therapy. * Systemic corticosteroid use for ≥3 months at a dose equivalent to ≥5 mg/day of prednisone. * Glomerular filtration rate (eGFR) \<30 mL/min. * New York Heart Association (NYHA) class III-IV heart failure. * Uncontrolled diabetes mellitus or hypertension. * Neurological disease significantly limiting walking. * Cognitive impairment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee osteoarthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis, knee osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Knee osteoarthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sisli Hamidiye Etfal Training and Research Hospital

    RECRUITING

    Istanbul, Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.